Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.
IPO Year:
Exchange: NASDAQ
Website: precipiodx.com
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
8-K - Precipio, Inc. (0001043961) (Filer)
10-Q - Precipio, Inc. (0001043961) (Filer)
8-K - Precipio, Inc. (0001043961) (Filer)
8-K - Precipio, Inc. (0001043961) (Filer)
10-Q - Precipio, Inc. (0001043961) (Filer)
8-K - Precipio, Inc. (0001043961) (Filer)
DEFA14A - Precipio, Inc. (0001043961) (Filer)
DEFA14A - Precipio, Inc. (0001043961) (Filer)
10-Q - Precipio, Inc. (0001043961) (Filer)
8-K - Precipio, Inc. (0001043961) (Filer)
SC 13G - Precipio, Inc. (0001043961) (Subject)
NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib
SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien
NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to note that a small contributing factor to the cash increase was the incoming cash collections that were expected in Q1, but were delayed and received in Q2 due to the impact of the Change Healthcare hack, as previously described. With cash reserves of approximately $1.3M at the end of Q2-2024, and its current pipeline of business, company management remains optimistic about the prospects of reaching breakeven by year end.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division's revenues will reach more than $1.5 million per month by year end, well above its breakeven goals.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. Under the agreement, Cardinal Health will market and distribute Precipio's HemeScreen portfolio of molecular assays to its customer base, which comprises primarily the acute healthcare systems (hospital networks), as well as reference laboratories and physician owned laboratories."The addition of this agreement with Cardinal Health, and alongside distribution agreements Precipio has with Fisher Healthcare and McKesson, strengthens our distribution network and positions us for growth in 2024", said Ilan Danie
First purchase order validates concept and ability to deliver affordable gigabit wireless to underserved marketsSAN JOSE, CA / ACCESSWIRE / January 24, 2024 / Peraso Inc. (NASDAQ:PRSO) ("Peraso" or the "Company") today announced an order for its Perspectus mmWave antenna modules that support the DUNE platform, demonstrating the Company's ability to address broadband infrastructure challenges in informal settlements.The DUNE platform implements intelligent Media Access Control features, which, along with the Perspectus series of modules, enable wireless Internet service provider (WISP) operators to deploy long range, multi-point networks without interference in dense user environments. Peraso
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces that continued revenue growth generated cash levels that bring the company closer to breakeven. Cash Burn From Operations (CBFO) declined by over 90% from the previous quarter, from approximately $1M/quarter in Q3-2023 to below $100k/quarter in the following recent quarter Q4-2023. Precipio's end of quarter cash balance changed from approximately $1.5M at the end of Q3-2024, to approximately $1.4M as of Dec 31, 2023. This was achieved without any significant increase in AP.While management is pleased with this accomplishment which continues to move the company forward towards breakeven, it cautions that Q1-2024 may n
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces it has entered into an agreement with a Japanese distributor for the sales and distribution of its products into the Japanese market. The distributor has already secured its first purchase order from a leading Japanese clinical laboratory, for Precipio's proprietary IV-Cell cytogenetics media. The first shipment is expected to be delivered at the end of Q1-2024.The Japanese diagnostic market is renowned for its high level of quality and for its intense scrutiny of products. Precipio was approached by a Japanese laboratory with an inquiry about its IV-Cell media, and entered into a testing period to evaluate the produ
Conference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10194411/fdf400
NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of this year (Version 2.2024—August 8, 2024). This is the only quantitative PCR-based panel of its kind on the market that distinguishes between CALR Type 1 and Type 2 alongside the other
NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable employees. Management is confident that the practical, strategic, and economic benefit to shareholders will ultimately be positive. Retaining valuable employees in an extremely competitive industry is key to ensuring the company's continued growth and success. "The company's achievement of its milestones would not have been possible without the hard work and dedication of its employees. Management believes it is in the shareholders' i
NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ET. The call will include updates on the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10191990/fd50f1a89e and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questions in advance shou
NEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to note that a small contributing factor to the cash increase was the incoming cash collections that were expected in Q1, but were delayed and received in Q2 due to the impact of the Change Healthcare hack, as previously described. With cash reserves of approximately $1.3M at the end of Q2-2024, and its current pipeline of business, company management remains optimistic about the prospects of reaching breakeven by year e
NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Pathology Division revenue in June reached its breakeven point, and the company anticipates continued growth in the next few months. We expect this division's revenues will reach more than $1.5 million per month by year end, well above its breakeven goals. The Products Division has three key accounts that are in the process of going live with a full portfolio of HemeScreen assays. The company is anticipating that at least t
NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that the company's 2024 Annual Meeting of Shareholders ("Annual Meeting") was convened and adjourned, without any business being conducted, due to lack of the required quorum. Message from Ilan Danieli, CEO: During this process, we've realized that there are quite a few shareholders who didn't know whether their shares were voted on or not. If you are not sure if your shares were voted, you should be able to see that information on your broker portal when you log in. If you can't find that information, please reach out to your broker and ask them – it's an easy
NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time. In order to ensure that there is a quorum required for the shareholders' meeting that is scheduled to take place tomorrow June 13, 2024 at 10 a.m. Eastern Time. At the time of this press release, approximately 44% of shares have been voted. For the company to hold the shareholder meeting, a minimum of 50% of shares must be voted. If the company is forced to adjourn the shareholder meeting due to insufficient votes, the costs of resch
NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) provides the following update to its shareholders on various business matters looking towards mid-year. 1. Business growthIn September of 2023, Precipio's pathology division exceeded its breakeven point of $15M annualized revenue run rate, resulting in a Q4 cash burn of less than $100K for the quarter. In the following quarter, as previously discussed, due to several operational issues, revenue declined below that point. We are pleased to report that the company has addressed the operational issues and as a result, pathology revenue is heading back tow
NEW HAVEN, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces it has secured a short-term loan facility of $500K to deal with any delays in cash collections due to the recent cybersecurity attack on Change Healthcare, a healthcare billing company used by a significant part of the healthcare market. Many healthcare businesses, including Precipio's Diagnostic Services division, rely on Change Healthcare (CH) to submit bills and collect cash from various payors and insurance companies for the services they provide. CH experienced a widely publicized cybersecurity attack in early 2024 that impacted the daily flow of cash rece
Conference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10194411/fdf400
NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ET. The call will include updates on the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10191990/fd50f1a89e and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questions in advance shou
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10187530/fbf7985e7e and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questio
NEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2023 corporate update call on November 20th, 2023 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10184562/fb122855b0 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questions
NEW HAVEN, Conn., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2023 corporate update call on August 17th at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10181824/fa30b78cc0 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questions in advan
NEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call to https://dpregister.com/sreg/10179242/f986f8e328 and will receive a calendar invite and a direct dial-in number, bypassing the operator. Listeners interested in submitting questions in advance s
NEW HAVEN, Conn., March 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4-2022 and year end shareholder update call on Monday, April 3rd at 5:00 PM ET. The call will include updates on the Company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10177120/f8d2d6fc60. For those that pre-register for the shareholder call, the host service will send a calendar invitation and a direct dial-in nu
NEW HAVEN, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2022 shareholder update call on Monday, November 14th at 5:00 PM ET. The call will include updates on the Company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10173003/f504ba2427. For those that pre-register for the shareholder call, the host service will send a calendar invitation and a direct dial-in number for t
NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2022 shareholder update call on Monday, August 15th at 5:00 PM ET. The call will include updates on the Company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10170261/f406cc5ea6. For those that pre-register for the shareholder call, the host service will send a calendar invitation and a direct dial-in number for t
NEW HAVEN, Conn., March 22, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4-2021 and year end shareholder update call on Monday, April 4th at 5:00 PM ET. The call will include updates on the Company's current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10164970/f20eec96a8. For those that pre-register for the shareholder call, the host service will send a calendar invitation and a direct dial-in nu